Analysts have clear opinions on GTHX.
Based on 4 analysts offering 12 month price targets for G1 Therapeutics in the last 3 months. The average price target is $67.00 with a high forecast of $74.00 and a low forecast of $55.00. The average price target represents a 220.11% increase from the
G1 Therapeutics, Inc. (GTHX) is followed by 4 analysts on the street.
Edward White from H.C. Wainwright rates it a Buy with a target of $72.00.
Similarly, Last month Chad Messer of Needham Reiterated a Buy with a target of $74.00.
The consensus on the street is Strong Buy.
What does G1 Therapeutics, Inc.(GTHX) do ?
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Ki
G1 Therapeutics, Inc. (GTHX) Insider Trades
Multiple company employees have indulged in significant insider trading. G1 Therapeutics, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
GC, Hanson James S. : P – Purchase(+$18,250) of GTHX in the trading session of 2018-12-26.
Dir Schwalm Cynthia : P – Purchase(+$26,196) of GTHX in the trading session of 2018-12-26.
Ch. Medical Officer, SVP R, D Malik Rajesh : S – Sale+OE(-$113,280) of G1 Therapeutics, Inc. in the trading session of 2018-12-17.